{"success":true,"data":{"pressRelease":{"id":"79473","rtpr_id":"nGNE5HVH8R","ticker":"EQSE","exchange":"Euronext Paris","all_tickers":["EQSE"],"title":"REG-RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2026","author":"Globe Newswire","published_at":"2026-07-02T16:00:00.212Z","article_body":"RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED \nTO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING \nOF 25 JUNE 2026\n\nNumber of shares comprising the share capital: 15,174,125\n\nNumber of shares with voting rights: 14,832,456\n\nNumber of shares with voting rights possessed by shareholders presents or\nrepresented or having voted by mail: 13,021,748\n\nThat means a quorum of 87.8% of the 14,832,456 shares with voting rights: the\nOrdinary Annual General Meeting was able to deliberate.\n\nThe Ordinary Annual General Meeting was held on Thursday, 25 June 2026 at 9:30\na.m. at the Company’s headquarters and approved the separate parent company\nand consolidated financial statements for the 2025 financial year. The results\nof the votes on the resolutions proposed at this meeting by the Board of\nDirectors were as follows:\n\n Resolutions Results of the votes \n * RESOLUTION ONE Resolution adopted by: * 13,009,592 votes in favour \n Approval of the annual financial statements * 0 vote against \n * 12,156 abstentions \n * RESOLUTION TWO Resolution adopted by: * 12,632,801 votes in favour \n Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement * 376,685 votes against \n * 12,262 abstentions \n * RESOLUTION THREE Resolution adopted by: * 12,926,592 votes in favour \n Approval of the consolidated financial statements * 83,000 votes against \n * 12,156 abstentions \n * RESOLUTION FOUR Resolution adopted by: * 12,986,842 votes in favour \n Appropriation of earnings, setting the dividend * 34,906 votes against \n * 0 abstention \n * RESOLUTION FIVE Resolution adopted by ( (*)): * 12,805,475 votes in favour \n Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code * 205,624 votes against \n * 10,649 abstentions \n * RESOLUTION SIX Resolution adopted by: * 10,977,791 votes in favour \n Ratification of the co-optation of Ms. Sylvie ORTILLON as Director * 2,043,747 votes against \n * 210 abstentions \n * RESOLUTION SEVEN Resolution adopted by: * 10,462,191 votes in favour \n Renewal of the term of office of Mr. François JACQUEL as Director * 2,559,347 votes against \n * 210 abstentions \n * RESOLUTION EIGHT Resolution adopted by: * 10,978,113 votes in favour \n Renewal of the term of office of Mr. Grégoire DE ROTALIER as Director * 1,925,939 votes against \n * 117,696 abstentions \n * RESOLUTION NINE Resolution adopted by: * 10,597,221 votes in favour \n Renewal of the term of office of LA COOPERATIVE WELCOOP as Director * 2,424,527 votes against \n * 0 abstention \n * RESOLUTION TEN Resolution adopted by: * 10,663,483 votes in favour \n Appointment of a new Independent Director (Ms. Céline DARGENT) * 2,358,265 votes against \n * 0 abstention \n * RESOLUTION ELEVEN Resolution adopted by: * 10,627,022 votes in favour \n Appointment of a new Director (Mr. Vincent MONESTEL) * 2,394,726 votes against \n * 0 abstention \n * RESOLUTION TWELVE Resolution adopted by: * 11,125,492 votes in favour \n Appointment of a new Director (Mr. François-Pierre MARQUIER) * 1,896,256 votes against \n * 0 abstention \n * RESOLUTION THIRTEEN Resolution adopted by: * 13,011,099 votes in favour \n Appointment of a Statutory Auditor * 0 vote against \n * 10,649 abstentions \n * RESOLUTION FOURTEEN Resolution adopted by: * 11,894,752 votes in favour \n Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2025 and mentioned in Article L. 22-10-9 of the French Commercial Code * 1,116,247 votes against \n * 10,749 abstentions \n * RESOLUTION FIFTEEN Resolution adopted by: * 13,003,287 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors * 7,712 votes against \n * 10,749 abstentions \n * RESOLUTION SIXTEEN Resolution adopted by: * 10,440,274 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Denis SUPPLISSON, Chief Executive Officer * 2,570,725 votes against \n * 10,749 abstentions \n * RESOLUTION SEVENTEEN Resolution adopted by: * 10,440,390 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Grégoire DE ROTALIER, Deputy CEO * 2,570,609 votes against \n * 10,749 abstentions \n * RESOLUTION EIGHTEEN Resolution adopted by: * 10,496,918 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Damien VALICON, Deputy CEO (non-Board member), until June 2, 2025 * 2,514,081 votes against \n * 10,749 abstentions \n * RESOLUTION NINETEEN Resolution adopted by: * 13,003,287 votes in favour \n Approval of the compensation policy for the Chairman of the Board of Directors for 2026 * 7,712 votes against \n * 10,749 abstentions \n * RESOLUTION TWENTY Resolution adopted by: * 10,601,036 votes in favour \n Approval of the compensation policy for the Chief Executive Officer for 2026 * 2,211,653 votes against \n * 209,059 abstentions \n * RESOLUTION TWENTY-ONE Resolution adopted by: * 10,601,152 votes in favour \n Approval of the compensation policy for the Deputy Chief Executive Officer(s) for 2026 * 2,211,537 votes against \n * 209,059 abstentions \n * RESOLUTION TWENTY-TWO Resolution adopted by: * 12,931,089 votes in favour \n Approval of the compensation policy for Directors * 79,910 votes against \n * 10,749 abstentions \n * TWENTY-THIRD RESOLUTION Resolution adopted by: * 12,965,785 votes in favour \n Setting total annual compensation for Directors for 2026 * 45,214 votes against \n * 10,749 abstentions \n * TWENTY-FOURTH RESOLUTION Resolution adopted by: * 11,364,336 votes in favour \n Authorisation by the Company to repurchase its own shares * 1,657,412 votes against \n * 0 abstention \n * TWENTY-FIFTH RESOLUTION Resolution adopted by: * 13,021,632 votes in favour \n Powers for formalities * 0 vote against \n * 116 abstentions \n\n((*) )After deduction of excluded voting rights\n\nFinancial Calendar:\n* Publication of H1 2026 revenue: 30 July 2026 (after market close) \n* Publication of H1 2026 results: 28 September 2026 (before market opening) \n* H1 2026 results presentation (SFAF): 28 September 2026 \n* Publication of Q3 2026 revenue: 28 October 2026 (after market close)\nAbout Equasens Group\n(https://www.globenewswire.com/Tracker?data=Ryj95mEqqMPZvpWVkEjJr9Ul8bbjBv1jREn2zyo3B_WfPgrQTA1d20b5dlG1JU-K0EpSUKTCCID0_JnceogbQyKp5u8PeUIH2YulAzOab30=) \n\nFounded over 35 years ago, Equasens Group, a leader in digital healthcare\nsolutions, today employs over 1.500 people across Europe.\nEquasens Group’s specialised business applications facilitate the day-to-day\nwork of healthcare professionals and their teams, working in private practice,\ncollaborative medical structures or healthcare establishments. The Group also\nprovides comprehensive support to healthcare professionals in the\ntransformation of their profession by developing electronic equipment, digital\nsolutions and healthcare robotics, as well as data hosting, financing and\ntraining adapted to their specific needs.\nAnd reflecting the spirit of its tagline \"Technology for a More Human\nExperience\", the Group is a leading provider of interoperability solutions\nthat improve coordination between healthcare professionals, their\ncommunications and data exchange resulting in better patient care and a more\nefficient and secure healthcare system.\n\nListed on Euronext Paris™ - Compartment B\n\nIndexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC(®) SMALL and CAC(®)\nAll-Tradable\nIncluded in the Euronext Tech Leaders segment and the European Rising Tech\nlabel\n\nEligible for the Deferred Settlement Service (“Service à Réglement\nDifféré” - SRD) and equity savings accounts invested in small and mid-caps\n(PEA-PME).\nISIN: FR 0012882389 – Ticker Code: EQS\n\nGet all the news about Equasens Group www.equasens.com and on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ScSquULqgglKCcj8J8Ci4B6WMaLJWDAxqBxHqAdNh7B9WSiYE2JevQKnYi-4O2lZGNEhn5LReQQ-ke5HHt5PQHRbgsqp_BQp6GleVinlaXk=)\n\nInvestor Relations and Media Contacts\n\n Equasens Group Investor Relations Chief Administrative and Financial Officer Frédérique Schmidt Tél. : +33 (0)3 83 15 90 67 frederique.schmidt@equasens.com NewCap Investor Relations Thomas Grojean Louis-Victor Delouvrier Tél : +33 (0)1 44 71 94 94 equasens@newcap.eu NewCap Financial media relations Nicolas Mérigeau Tél : +33 (0)1 44 71 94 94 equasens@newcap.eu \n\nForward-looking statements\n\nThis press release contains forward-looking statements that are not guarantees\nof future performance and are based on current opinions, forecasts and\nassumptions, including, but not limited to, assumptions about Equasens'\ncurrent and future strategy and the environment in which Equasens operates.\nThese involve known and unknown risks, uncertainties and other factors, which\nmay cause actual results, performance or achievements, or industry results or\nother events, to materially differ from those expressed in or implied by such\nforward-looking statements. These risks and uncertainties include those\ndetailed in Chapter 3 \"Risk factors\" of the Universal Registration Document\nfiled with the French financial market authority (Autorité des Marchés\nFinanciers or AMF) on April 29, 2025 under number D.25-0334. These\nforward-looking statements are valid only as of the date of this press\nrelease.\n\nAttachment\n* PR_RESULTS OF THE VOTES_EN_Vdef\n(https://ml-eu.globenewswire.com/Resource/Download/44fa17ab-4a00-411c-bcb7-52dcf0756f0a)","article_body_html":"","raw_payload":{"data":{"id":"nGNE5HVH8R","title":"REG-RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2026","author":"Globe Newswire","ticker":"EQSE","created":"2026-07-02T16:00:00.212Z","tickers":["EQSE"],"exchange":"Euronext Paris","article_body":"RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED \nTO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING \nOF 25 JUNE 2026\n\nNumber of shares comprising the share capital: 15,174,125\n\nNumber of shares with voting rights: 14,832,456\n\nNumber of shares with voting rights possessed by shareholders presents or\nrepresented or having voted by mail: 13,021,748\n\nThat means a quorum of 87.8% of the 14,832,456 shares with voting rights: the\nOrdinary Annual General Meeting was able to deliberate.\n\nThe Ordinary Annual General Meeting was held on Thursday, 25 June 2026 at 9:30\na.m. at the Company’s headquarters and approved the separate parent company\nand consolidated financial statements for the 2025 financial year. The results\nof the votes on the resolutions proposed at this meeting by the Board of\nDirectors were as follows:\n\n Resolutions Results of the votes \n * RESOLUTION ONE Resolution adopted by: * 13,009,592 votes in favour \n Approval of the annual financial statements * 0 vote against \n * 12,156 abstentions \n * RESOLUTION TWO Resolution adopted by: * 12,632,801 votes in favour \n Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement * 376,685 votes against \n * 12,262 abstentions \n * RESOLUTION THREE Resolution adopted by: * 12,926,592 votes in favour \n Approval of the consolidated financial statements * 83,000 votes against \n * 12,156 abstentions \n * RESOLUTION FOUR Resolution adopted by: * 12,986,842 votes in favour \n Appropriation of earnings, setting the dividend * 34,906 votes against \n * 0 abstention \n * RESOLUTION FIVE Resolution adopted by ( (*)): * 12,805,475 votes in favour \n Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code * 205,624 votes against \n * 10,649 abstentions \n * RESOLUTION SIX Resolution adopted by: * 10,977,791 votes in favour \n Ratification of the co-optation of Ms. Sylvie ORTILLON as Director * 2,043,747 votes against \n * 210 abstentions \n * RESOLUTION SEVEN Resolution adopted by: * 10,462,191 votes in favour \n Renewal of the term of office of Mr. François JACQUEL as Director * 2,559,347 votes against \n * 210 abstentions \n * RESOLUTION EIGHT Resolution adopted by: * 10,978,113 votes in favour \n Renewal of the term of office of Mr. Grégoire DE ROTALIER as Director * 1,925,939 votes against \n * 117,696 abstentions \n * RESOLUTION NINE Resolution adopted by: * 10,597,221 votes in favour \n Renewal of the term of office of LA COOPERATIVE WELCOOP as Director * 2,424,527 votes against \n * 0 abstention \n * RESOLUTION TEN Resolution adopted by: * 10,663,483 votes in favour \n Appointment of a new Independent Director (Ms. Céline DARGENT) * 2,358,265 votes against \n * 0 abstention \n * RESOLUTION ELEVEN Resolution adopted by: * 10,627,022 votes in favour \n Appointment of a new Director (Mr. Vincent MONESTEL) * 2,394,726 votes against \n * 0 abstention \n * RESOLUTION TWELVE Resolution adopted by: * 11,125,492 votes in favour \n Appointment of a new Director (Mr. François-Pierre MARQUIER) * 1,896,256 votes against \n * 0 abstention \n * RESOLUTION THIRTEEN Resolution adopted by: * 13,011,099 votes in favour \n Appointment of a Statutory Auditor * 0 vote against \n * 10,649 abstentions \n * RESOLUTION FOURTEEN Resolution adopted by: * 11,894,752 votes in favour \n Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2025 and mentioned in Article L. 22-10-9 of the French Commercial Code * 1,116,247 votes against \n * 10,749 abstentions \n * RESOLUTION FIFTEEN Resolution adopted by: * 13,003,287 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors * 7,712 votes against \n * 10,749 abstentions \n * RESOLUTION SIXTEEN Resolution adopted by: * 10,440,274 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Denis SUPPLISSON, Chief Executive Officer * 2,570,725 votes against \n * 10,749 abstentions \n * RESOLUTION SEVENTEEN Resolution adopted by: * 10,440,390 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Grégoire DE ROTALIER, Deputy CEO * 2,570,609 votes against \n * 10,749 abstentions \n * RESOLUTION EIGHTEEN Resolution adopted by: * 10,496,918 votes in favour \n Approval of the components of compensation paid in 2025 to Mr. Damien VALICON, Deputy CEO (non-Board member), until June 2, 2025 * 2,514,081 votes against \n * 10,749 abstentions \n * RESOLUTION NINETEEN Resolution adopted by: * 13,003,287 votes in favour \n Approval of the compensation policy for the Chairman of the Board of Directors for 2026 * 7,712 votes against \n * 10,749 abstentions \n * RESOLUTION TWENTY Resolution adopted by: * 10,601,036 votes in favour \n Approval of the compensation policy for the Chief Executive Officer for 2026 * 2,211,653 votes against \n * 209,059 abstentions \n * RESOLUTION TWENTY-ONE Resolution adopted by: * 10,601,152 votes in favour \n Approval of the compensation policy for the Deputy Chief Executive Officer(s) for 2026 * 2,211,537 votes against \n * 209,059 abstentions \n * RESOLUTION TWENTY-TWO Resolution adopted by: * 12,931,089 votes in favour \n Approval of the compensation policy for Directors * 79,910 votes against \n * 10,749 abstentions \n * TWENTY-THIRD RESOLUTION Resolution adopted by: * 12,965,785 votes in favour \n Setting total annual compensation for Directors for 2026 * 45,214 votes against \n * 10,749 abstentions \n * TWENTY-FOURTH RESOLUTION Resolution adopted by: * 11,364,336 votes in favour \n Authorisation by the Company to repurchase its own shares * 1,657,412 votes against \n * 0 abstention \n * TWENTY-FIFTH RESOLUTION Resolution adopted by: * 13,021,632 votes in favour \n Powers for formalities * 0 vote against \n * 116 abstentions \n\n((*) )After deduction of excluded voting rights\n\nFinancial Calendar:\n* Publication of H1 2026 revenue: 30 July 2026 (after market close) \n* Publication of H1 2026 results: 28 September 2026 (before market opening) \n* H1 2026 results presentation (SFAF): 28 September 2026 \n* Publication of Q3 2026 revenue: 28 October 2026 (after market close)\nAbout Equasens Group\n(https://www.globenewswire.com/Tracker?data=Ryj95mEqqMPZvpWVkEjJr9Ul8bbjBv1jREn2zyo3B_WfPgrQTA1d20b5dlG1JU-K0EpSUKTCCID0_JnceogbQyKp5u8PeUIH2YulAzOab30=) \n\nFounded over 35 years ago, Equasens Group, a leader in digital healthcare\nsolutions, today employs over 1.500 people across Europe.\nEquasens Group’s specialised business applications facilitate the day-to-day\nwork of healthcare professionals and their teams, working in private practice,\ncollaborative medical structures or healthcare establishments. The Group also\nprovides comprehensive support to healthcare professionals in the\ntransformation of their profession by developing electronic equipment, digital\nsolutions and healthcare robotics, as well as data hosting, financing and\ntraining adapted to their specific needs.\nAnd reflecting the spirit of its tagline \"Technology for a More Human\nExperience\", the Group is a leading provider of interoperability solutions\nthat improve coordination between healthcare professionals, their\ncommunications and data exchange resulting in better patient care and a more\nefficient and secure healthcare system.\n\nListed on Euronext Paris™ - Compartment B\n\nIndexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC(®) SMALL and CAC(®)\nAll-Tradable\nIncluded in the Euronext Tech Leaders segment and the European Rising Tech\nlabel\n\nEligible for the Deferred Settlement Service (“Service à Réglement\nDifféré” - SRD) and equity savings accounts invested in small and mid-caps\n(PEA-PME).\nISIN: FR 0012882389 – Ticker Code: EQS\n\nGet all the news about Equasens Group www.equasens.com and on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ScSquULqgglKCcj8J8Ci4B6WMaLJWDAxqBxHqAdNh7B9WSiYE2JevQKnYi-4O2lZGNEhn5LReQQ-ke5HHt5PQHRbgsqp_BQp6GleVinlaXk=)\n\nInvestor Relations and Media Contacts\n\n Equasens Group Investor Relations Chief Administrative and Financial Officer Frédérique Schmidt Tél. : +33 (0)3 83 15 90 67 frederique.schmidt@equasens.com NewCap Investor Relations Thomas Grojean Louis-Victor Delouvrier Tél : +33 (0)1 44 71 94 94 equasens@newcap.eu NewCap Financial media relations Nicolas Mérigeau Tél : +33 (0)1 44 71 94 94 equasens@newcap.eu \n\nForward-looking statements\n\nThis press release contains forward-looking statements that are not guarantees\nof future performance and are based on current opinions, forecasts and\nassumptions, including, but not limited to, assumptions about Equasens'\ncurrent and future strategy and the environment in which Equasens operates.\nThese involve known and unknown risks, uncertainties and other factors, which\nmay cause actual results, performance or achievements, or industry results or\nother events, to materially differ from those expressed in or implied by such\nforward-looking statements. These risks and uncertainties include those\ndetailed in Chapter 3 \"Risk factors\" of the Universal Registration Document\nfiled with the French financial market authority (Autorité des Marchés\nFinanciers or AMF) on April 29, 2025 under number D.25-0334. These\nforward-looking statements are valid only as of the date of this press\nrelease.\n\nAttachment\n* PR_RESULTS OF THE VOTES_EN_Vdef\n(https://ml-eu.globenewswire.com/Resource/Download/44fa17ab-4a00-411c-bcb7-52dcf0756f0a)"},"type":"article","timestamp":"2026-07-02T16:00:00.475694036Z","server_sent_at_ms":1783008000475},"received_at":"2026-07-02T16:00:00.640Z","source_url":null},"analysis":{"id":"68721","press_release_id":"79473","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["Approximately 20% of votes were cast against the compensation packages for the CEO and Deputy CEOs","Approximately 15% of votes were cast against the ratification of Director Sylvie Ortillon"],"eventType":"other","narrative":"Equasens Group shareholders approved all resolutions at the Ordinary Annual General Meeting held on June 25, 2026, with a quorum of 87.8% of voting rights.\n\nThe meeting ratified the co-optation of Sylvie Ortillon and renewed the terms of François Jacquel and Grégoire De Rotalier, while appointing Céline Dargent, Vincent Monestel, and François-Pierre Marquier as new directors.\n\nShareholders authorized the appropriation of earnings to set the dividend and approved an authorization for the company to repurchase its own shares; the company scheduled H1 2026 revenue publication for July 30 and full H1 results for September 28.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine AGM results include buyback authorization despite significant dissent on executive compensation."},"keyFigures":{"customDimensions":{"employees":"over 1,500","quorum_percent":"87.8%","h1_2026_results_date":"28 September 2026","h1_2026_revenue_date":"30 July 2026","q3_2026_revenue_date":"28 October 2026","shares_voting_rights":14832456}},"quotedText":"","namedEntities":{"people":[{"name":"Sylvie ORTILLON","role":"Director"},{"name":"François JACQUEL","role":"Director"},{"name":"Grégoire DE ROTALIER","role":"Director and Deputy CEO"},{"name":"Céline DARGENT","role":"Independent Director"},{"name":"Vincent MONESTEL","role":"Director"},{"name":"François-Pierre MARQUIER","role":"Director"},{"name":"Thierry CHAPUSOT","role":"Chairman of the Board"},{"name":"Denis SUPPLISSON","role":"Chief Executive Officer"},{"name":"Damien VALICON","role":"Deputy CEO"},{"name":"Frédérique Schmidt","role":"Chief Administrative and Financial Officer"},{"name":"Thomas Grojean","role":"Investor Relations"},{"name":"Louis-Victor Delouvrier","role":"Investor Relations"},{"name":"Nicolas Mérigeau","role":"Media Relations"}],"products":[],"companies":[{"name":"Equasens Group","ticker":"EQSE"},{"name":"LA COOPERATIVE WELCOOP","relationship":"Corporate Director"},{"name":"NewCap","relationship":"Investor Relations Firm"},{"name":"Euronext Paris"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine filing of voting results from the Ordinary Annual General Meeting. All resolutions were passed, including routine director renewals, dividend approval, and share buyback authorization, with no unexpected corporate actions disclosed."},"tickerRelevance":{"others":[],"primary":"EQSE"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["board_change","buyback","dividend"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_agm","sectorWeight":"health_care_it"}},"event_type":"other","event_type_secondary":["board_change","buyback","dividend"],"sentiment":"bullish","material_impact_score":1,"narrative":"Equasens Group shareholders approved all resolutions at the Ordinary Annual General Meeting held on June 25, 2026, with a quorum of 87.8% of voting rights.\n\nThe meeting ratified the co-optation of Sylvie Ortillon and renewed the terms of François Jacquel and Grégoire De Rotalier, while appointing Céline Dargent, Vincent Monestel, and François-Pierre Marquier as new directors.\n\nShareholders authorized the appropriation of earnings to set the dividend and approved an authorization for the company to repurchase its own shares; the company scheduled H1 2026 revenue publication for July 30 and full H1 results for September 28.","key_figures":{"customDimensions":{"employees":"over 1,500","quorum_percent":"87.8%","h1_2026_results_date":"28 September 2026","h1_2026_revenue_date":"30 July 2026","q3_2026_revenue_date":"28 October 2026","shares_voting_rights":14832456}},"named_entities":{"people":[{"name":"Sylvie ORTILLON","role":"Director"},{"name":"François JACQUEL","role":"Director"},{"name":"Grégoire DE ROTALIER","role":"Director and Deputy CEO"},{"name":"Céline DARGENT","role":"Independent Director"},{"name":"Vincent MONESTEL","role":"Director"},{"name":"François-Pierre MARQUIER","role":"Director"},{"name":"Thierry CHAPUSOT","role":"Chairman of the Board"},{"name":"Denis SUPPLISSON","role":"Chief Executive Officer"},{"name":"Damien VALICON","role":"Deputy CEO"},{"name":"Frédérique Schmidt","role":"Chief Administrative and Financial Officer"},{"name":"Thomas Grojean","role":"Investor Relations"},{"name":"Louis-Victor Delouvrier","role":"Investor Relations"},{"name":"Nicolas Mérigeau","role":"Media Relations"}],"products":[],"companies":[{"name":"Equasens Group","ticker":"EQSE"},{"name":"LA COOPERATIVE WELCOOP","relationship":"Corporate Director"},{"name":"NewCap","relationship":"Investor Relations Firm"},{"name":"Euronext Paris"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-05T14:46:31.542Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_agm","sectorWeight":"health_care_it"}},"durationMs":150486,"modelName":"george-droid-qwen-72b"}}